|
|
|
|
|
|
|
|
|
|
|
|
|
|
Previous: NEW GERMANY FUND INC, N-23C-1, 2000-11-02 |
Next: MEDICIS PHARMACEUTICAL CORP, 8-K, EX-99.1, 2000-11-02 |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: November 2, 2000
(Date of earliest event reported: September 29, 2000)
Medicis Pharmaceutical Corporation
(Exact name of registrant as specified in its charter)
| Delaware | 0-18443 | 52-1574808 | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 8125 North Hayden Road, Scottsdale, Arizona | 85258 | |
| (Address of principal executive offices) | (Zip Code) | |
| |
||
| Registrant’s telephone number, including area code | (602) 808-8800 | |
| |
||
| 4343 East Camelback Road, Phoenix, Arizona | 85018 | |
| (Former name or former address, if changed since last report) | (Zip Code) |
Item 5. Other Events.
On September 29, 2000, the Development, Commercialization and License Agreement, dated as of August 15, 2000 (the “Agreement”), by and between the Registrant and Corixa Corporation (“Corixa”) became effective. The Agreement provides for a strategic alliance by and between the Registrant and Corixa regarding Corixa’s psoriasis immunotherapeutic product, PVAC™ treatment. Upon effectiveness the Registrant made a non-refundable payment of $17 million to Corixa. A description of the collaboration was disclosed in a press release filed with the Securities and Exchange Commission on August 15, 2000 on Form 8-K.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(a) Financial Statements of Businesses Acquired.
Not Applicable.
(b) Pro Forma Financial Information.
Not Applicable.
(c) Exhibits.
99.1* Development, Commercialization and License Agreement dated August 15, 2000.
* Document for which confidential treatment has been requested.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Medicis Pharmaceutical Corporation |
||
| |
||
| By: | /s/ MARK A. PRYGOCKI, SR. Mark A. Prygocki, Sr. Chief Financial Officer |
|
Date: November 2, 2000
EXHIBIT INDEX
| Exhibit Number |
Description |
|
| 99.1* | Development, Commercialization and License Agreement dated August 15, 2000. |
*Document for which confidential treatment has been requested.
|
|